Welcome to Anavex Life Sciences Corp. We are working to develop novel small molecule treatments for some of the most challenging central nervous system (CNS) diseases facing society today, including Alzheimer’s, Parkinson’s, Rett syndrome, and other rare diseases. We believe that targeting the upstream Sigma-1 receptor (SIGMAR1), through our proprietary SIGMACEPTOR™ discovery platform, has the capability to unlock the body’s own defenses to treat, and in some cases potentially reverse, CNS conditions. Following the completion of several promising clinical trials, we are progressing from our research focus to a commercial stage company working towards bringing our treatments to market to benefit patients across the globe and ensure access to our new CNS treatment paradigm.
Our product portfolio platform is inspired by the lived experiences of the people living with neurodegenerative and neurodevelopmental disorders and the strength and dedication of carers.
Recent research findings suggest that the small molecule therapeutic candidates produced by our proprietary portfolio platform establishes novel modes of action aimed at a variety of CNS disorders like Alzheimer's disease, Parkinson's disease, Rett syndrome and others.
Our proprietary SIGMACEPTOR™ discovery platform produces therapeutic candidates that lead to the modulation of SIGMAR1. Data suggests that activation of SIGMAR1 results in the restoration of complete housekeeping function within the body and is pivotal to neural cell homeostasis and neuroplasticity.
Anavex Life Sciences presents at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023.
News & Events
A therapeutic approach for all ages
The SIGMACEPTOR™ Discovery Platform is designed to produce therapeutic candidates for people of all ages. From neurodevelopment to neurodegenerative conditions, our SIGMAR1 portfolio platform enables therapeutic discovery utilizing the body's own defense mechanism to restore function.
“Assisting the body in re-establishing homeostasis could very well be a key therapeutic step to solving several life-altering CNS conditions.”
Christopher U. Missling PhD, MS, MBA
President and CEO